SCHEMBL3679586

SCHEMBL3679586

Cc1cc(OB(O)O)cc(C)c1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.46
CA2 P00918 1/20 0.46
PTGS1 P23219 8/20 0.37
PTGS2 P35354 8/20 0.37
ALOX5 P09917 6/20 0.37
ESR1 P03372 2/20 0.37
ESR2 Q92731 1/20 0.37
ALDH1A1 P00352 3/20 0.35
GAA P10253 2/20 0.33
CYP1A2 P05177 2/20 0.33
CYP2C9 P11712 2/20 0.33
ACHE P22303 1/20 0.33
KDM4E B2RXH2 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2B6 P20813 1/20 0.33
MEN1 O00255 1/20 0.33
G6PD P11413 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3679584 0.83 CA1 (0.48) CA1CA2PTGS1PTGS2ALOX5
SCHEMBL4851060 0.83 TUBB1 (0.32) LMNACYP3A4
SCHEMBL4088743 0.77 ALDH1A1 (0.38) CA1CA2ALDH1A1ACHEMAPT
SCHEMBL4578633 0.76 ALDH1A1 (0.32) ALDH1A1
SCHEMBL28234038 0.76 TP53 (0.46) ESR1ESR2ALDH1A1CYP1A2CYP2C9
SCHEMBL4086875 0.75 ALDH1A1 (0.41) ALDH1A1CYP2C9ACHEMAPTCYP3A4
SCHEMBL4859496 0.74 TDP1 (0.46) ALDH1A1LMNAMAPTMEN1KMT2A
SCHEMBL580906 0.74 CA1 (0.55) CA1CA2PTGS1PTGS2ALOX5
Ammonia Solution, Strong SCHEMBL29088797 0.73 ALDH1A1 (0.39) ALDH1A1CYP2C9ACHEMAPTCYP3A4
SCHEMBL27831721 0.73 ALDH1A1 (0.39) ALDH1A1CYP2C9ACHEMAPTCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0863919-B1 SUPPORTED CATALYST CONTAINING TETHERED CATION FORMING ACTIVATOR DOW CHEMICAL CO (US) 2000-11-15 EP claimed
US-7722784-B2 Liquid crystal composition, liquid crystal device, reflection display material, light modulating material, and anthraquinone compound FUJIFILM CORPORATION (JP) 2010-05-25 US disclosed
US-20090074991-A1 LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL DEVICE, REFLECTION DISPLAY MATERIAL, LIGHT MODULATING MATERIAL, AND ANTHRAQUINONE COMPOUND FUJIFILM CORPORATION (JP) 2009-03-19 US disclosed
EP-1123321-B1 SUPPORTED BIDENTATE AND TRIDENTATE CATALYST COMPOSITIONS AND OLEFIN POLYMERIZATION USING SAME GRACE W R & CO (US) 2006-12-20 EP disclosed
CN-1146583-C Supported bidentate and tridentate catalyst compositions and olefin polymerization using same 2004-04-21 CN disclosed
CN-1328576-A Supported bidentate and tridentate catalyst compositions and olefin polymerization using same GRACE W R & CO (US) 2001-12-26 CN disclosed
EP-1123321-A1 SUPPORTED BIDENTATE AND TRIDENTATE CATALYST COMPOSITIONS AND OLEFIN POLYMERIZATION USING SAME W.R. Grace & Co.-Conn. (US) 2001-08-16 EP disclosed
WO-2000020467-A1 SUPPORTED BIDENTATE AND TRIDENTATE CATALYST COMPOSITIONS AND OLEFIN POLYMERIZATION USING SAME W.R. GRACE & CO.-CONN (US) 2000-04-13 WO disclosed
CN-1202909-A Supported catalyst containing tetherod cation forming activator DOW CHEMICAL CO (US) 1998-12-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090074991-A1 LIQUID CRYSTAL COMPOSITION, LIQUID CRYSTAL DEVICE, REFLECTION DISPLAY MATERIAL, LIGHT MODULATING MATERIAL, AND ANTHRAQUINONE COMPOUND CXCR1, CRY1, NLRP1 CA1 1360/4885CA2 2867/4885PTGS1 2549/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.